Christel S. R.
- Country
- France
- Department
- N/A
Research Overview
- Phase 3b/4 Randomized Double‑Blind Study of Depemokimab 100 mg SC Q26 weeks vs Placebo on Exacerbations and Lung‑Function Decline in Adults/Adolescents with Type 2 Asthma
- Evaluation of Benralizumab's Predictive Gene Expression Signature in Reducing Exacerbations in Severe Asthma Patients
- Non-Inferiority Trial of Depemokimab Versus Mepolizumab or Benralizumab in Severe Eosinophilic Asthma Patients
Data & Insights
Has run more than one trial at 113 of 291 partner sites.
Specializations
Severe Asthma Management
This investigator specializes in treating severe asthma with particular emphasis on eosinophilic phenotypes. Their research focuses on innovative therapeutic approaches for patients whose condition remains uncontrolled with standard treatments.
- Eosinophilic Asthma Therapeutics
- Treatment Optimization Strategies
- Biological Therapy Assessment
Biological Therapeutics
The investigator evaluates various biological treatments including benralizumab, tezepelumab, and dupilumab. Their work encompasses assessment of treatment efficacy and exploration of optimal duration protocols.
- Response Prediction Studies
- Long-term Treatment Outcomes
- Therapy Withdrawal Assessment
Clinical Innovation
Their research extends to comparative therapeutic studies and treatment optimization for severe asthma patients. The investigator examines airway remodeling and explores predictive markers for treatment response.
- Biomarker Analysis
- Treatment Response Patterns
- Maintenance Therapy Reduction
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.